Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1986 Apr;21(3):169–173. doi: 10.1007/BF00199357

Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine

Isaiah J Fidler 1,✉
PMCID: PMC11038095  PMID: 3698058

Abstract

The purpose of these studies was to determine the optimal conditions and limitations for the eradication of spontaneous melanoma metastases by the systemic administration of liposomes containing MTP-PE. Mice whose primary melanoma had been excised were given i.v. injections of liposomes at various schedules. Optimal treatment was achieved by twice weekly administration for 4 weeks (eight i.v. injections). Bioassays failed to reveal the presence of melanoma cells in lungs of mice surviving to day 250 of the experiment. The success of liposome treatment of metastases diminished when the first i. v. injection of liposomes-MTP-PE commenced on day 10 after surgical excision of the local melanoma, as compared with day 3 or day 7 after surgery. We conclude that the major limitation for macrophage-mediated destruction of metastases is the number of tumor cells in the lesions. Because of this limitation, it is unlikely that the systemic activation of macrophages could be used as a single modality for treatment of advanced metastases.

Keywords: Tumor Cell, Melanoma, Optimal Condition, Melanoma Cell, Systemic Treatment

References

  • 1.Alving CR. Delivery of liposome-encapsulated drugs to macrophages. Pharmacol Ther. 1983;22:407. doi: 10.1016/0163-7258(83)90010-4. [DOI] [PubMed] [Google Scholar]
  • 2.Deodhar SD, Barna BP, Edinger M, Chiang T. Inhibition of lung metastases by liposomal immunotherapy in a murine fibrosarcoma model. J Biol Response Mod. 1982;1:27. [Google Scholar]
  • 3.Fidler IJ. Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science. 1980;208:1469. doi: 10.1126/science.7384789. [DOI] [PubMed] [Google Scholar]
  • 4.Fidler IJ. The in situ induction of tumoricidal activity in alveolar macrophages by liposomes containing muramyl dipeptide is a thymus-independent process. J Immunol. 1981;127:1719. [PubMed] [Google Scholar]
  • 5.Fidler IJ, Kleinerman ES. Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol. 1984;2(8):937. doi: 10.1200/JCO.1984.2.8.937. [DOI] [PubMed] [Google Scholar]
  • 6.Fidler IJ, Poste G. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Springer Semin Immunopathol. 1982;5:161. doi: 10.1007/BF00199794. [DOI] [PubMed] [Google Scholar]
  • 7.Fidler IJ, Schroit AJ. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: In situ activation of macrophages and therapy of spontaneous cancer metastasis. J Immunol. 1984;133(1):515. [PubMed] [Google Scholar]
  • 8.Fidler IJ, Raz A, Fogler WE, Kirsh R, Bugelski P, Poste G. The design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res. 1980;40:4460. [PubMed] [Google Scholar]
  • 9.Fidler IJ, Sone S, Fogler WE, Barnes ZL. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injections of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA. 1981;78:1680. doi: 10.1073/pnas.78.3.1680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Fidler IJ, Sone S, Fogler WE, Smith D, Braun DG, Tarcsay L, Gisler RJ, Schroit AJ. Efficacy of liposomes containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of alveolar macrophages in vivo. J Biol Response Mod. 1982;1:43. [Google Scholar]
  • 11.Fidler IJ, Barnes Z, Fogler WE, Kirsh R, Bugelski P, Poste G. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res. 1982;42:496. [PubMed] [Google Scholar]
  • 12.Fidler IJ, Fogler WE, Tarcsay L, Schumann G, Braun DG, Schroit AJ. Advances in immunopharmacology, vol. 2. Oxford: Pergamon Press; 1983. Systemic activation of macrophages and treatment of cancer metastasis by liposomes containing hydrophilic or lipophilic muramyl dipeptide; p. 235. [Google Scholar]
  • 13.Fogler WE, Fidler IJ. Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages. Cancer Res. 1985;45:14. [PubMed] [Google Scholar]
  • 14.Fogler WE, Raz A, Fidler IJ. In situ activation of murine macrophages by liposomes containing lymphokines. Cell Immunol. 1980;53:214. doi: 10.1016/0008-8749(80)90440-2. [DOI] [PubMed] [Google Scholar]
  • 15.Griswold DP Jr (1972) Consideration of the subcutaneously implanted B16 melanoma as a screening model for potential anticancer agents. Cancer Chemother Rep 3:315 [PubMed]
  • 16.Hart IR. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol. 1979;97:587. [PMC free article] [PubMed] [Google Scholar]
  • 17.Key ME, Talmadge JE, Fogler WE, Bucana C, Fidler IJ. Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. J Natl Cancer Inst. 1982;69:1189. [PubMed] [Google Scholar]
  • 18.Kleinerman ES, Schroit AJ, Fogler WE, Fidler IJ. Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines. J Clin Invest. 1983;72:1. doi: 10.1172/JCI110970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res. 1983;43:2010. [PubMed] [Google Scholar]
  • 20.Kleinerman ES, Zicht R, Sarin PS, Gallo RC, Fidler IJ. Constitutive production and release of a lymphokine with macrophage-activating factor activity distinct from gamma-interferon by a human T-cell leukemia viruspositive cell line. Cancer Res. 1984;44:4470. [PubMed] [Google Scholar]
  • 21.Lopez-Berestein G, Mehta K, Mehta R, Juliano RL, Hersh EM. The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. J Immunol. 1983;130:1500. [PubMed] [Google Scholar]
  • 22.Lopez-Berestein G, Milas L, Hunter N, Mehta K, Eppstein D, VanderPas MA, Mathews TR, Hersh EM. Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome encapsulated 6-O-steroyl-N-acetylmuramyl-L-aminobutyryl-D-isoglutamine. Clin Exp Metastasis. 1984;2(2):336. doi: 10.1007/BF00052413. [DOI] [PubMed] [Google Scholar]
  • 23.Mehta K, Lopez-Berestein G, Hersh EM, Juliano RL. Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes. J Reticuloendothel Soc. 1982;32:155. [PubMed] [Google Scholar]
  • 24.Nicolau C, Paraf A. Liposomes, drugs and immunocompetent cell functions. London: Academic Press; 1981. [Google Scholar]
  • 25.Phillips NC, Mora ML, Chedid L, Lefrancier P, Bernard JM. Activation of tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res. 1985;45:128. [PubMed] [Google Scholar]
  • 26.Poste G, Kirsh R, Fogler W, Fidler IJ. Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. Cancer Res. 1979;39:881. [PubMed] [Google Scholar]
  • 27.Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 1982;42:1412. [PubMed] [Google Scholar]
  • 28.Poste G, Kirsh R, Bugelski P. Liposomes as a drug delivery system in cancer therapy. In: Sunkara P, editor. Novel approaches to cancer chemotherapy. New York: Academic Press; 1984. p. 323. [Google Scholar]
  • 29.Saiki I, Fidler IJ. Synergistic activation by recombinant mouse gamma-interferon and muramyl dipeptide of tumoricidal properties in mouse macrophages. J Immunol. 1985;135:684. [PubMed] [Google Scholar]
  • 30.Schroit AJ, Fidler IJ. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res. 1982;42:161. [PubMed] [Google Scholar]
  • 31.Schroit AJ, Galligioni E, Fidler IJ. Factors influencing the in situ activation of macrophages by liposomes containing muramyl dipeptide. Biol Cell. 1983;47:87. [Google Scholar]
  • 32.Schroit AJ, Hart IR, Madsen J, Fidler IJ. Selective delivery of drugs encapsulated in liposomes: Natural targeting to macrophages involved in varius disease states. J Biol Response Mod. 1983;2:97. [PubMed] [Google Scholar]
  • 33.Sone S, Fidler IJ. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. J Immunol. 1980;125:2454. [PubMed] [Google Scholar]
  • 34.Sone S, Fidler IJ. In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes. Cell Immunol. 1981;57:42. doi: 10.1016/0008-8749(81)90118-0. [DOI] [PubMed] [Google Scholar]
  • 35.Sone S, Tsubura E. Human alveolar macrophages: Potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide. J Immunol. 1982;129:1313. [PubMed] [Google Scholar]
  • 36.Sone S, Poste G, Fidler IJ. Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines. J Immunol. 1980;124:2197. [PubMed] [Google Scholar]
  • 37.Talmadge JE, Key M, Fidler IJ. Macrophage content of metastatic and nonmetastatic rodent neoplasms. J Immunol. 1981;126:2245. [PubMed] [Google Scholar]
  • 38.Thomas DG, Breslow N, Gart JJ. Trend and homogeneity analyses of proportions and life table data. Comput Biomed Res. 1977;10:373. doi: 10.1016/0010-4809(77)90006-4. [DOI] [PubMed] [Google Scholar]
  • 39.Xu ZL, Bucana CD, Fidler IJ. In vitro activation of murine Kupffer cells by lymphokines or endotoxins to lyse syngeneic tumor cells. Am J Pathol. 1984;117:372. [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES